Session 3: Boosting primary and recurrent rectal cancer: how far can we push the radiotherapy envelope?
Where this comes from
- Record sourced from PubMed, PMID 29878674.
- Also identified by DOI 10.1111/codi.14086.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant pelvic radiotherapy is widely used for patients with advanced rectal cancer. The trade-off between dose and response is well-established, yet little consensus remains on the precise methods of delivery and doses given in different scenarios. Professor Vuong reviews the evidence base and trial evidence on the escalation of radiotherapy dose and the methods of achieving this.
Medical subject headings
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
- Radiosurgery
- Radiotherapy, Intensity-Modulated
- Rectal Neoplasms